Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bolaget.

Datum Källa Rubrik Typ Alternativ
2022-12-23 Emergers Emergers: Equity Research | NANEXA: Novo Nordisk deal offers both scientific validation and investor-friendly financing Analyser Ladda ner | Visa Stäng
2022-12-21 Nanexa Inbjudan till nyhetskommentar med anledning av Nanexas nyhetssläpp den 21 december 2022 Analyser Ladda ner | Visa Stäng
2022-12-21 Nanexa Invitation to commentary regarding Nanexa's press release on 21 December 2022 Analyser Ladda ner | Visa Stäng
2022-12-21 Nanexa Nanexa signs an exclusivity and evaluation agreement worth SEK 46.1 million and completes a directed share issue of SEK 17.2 million to Novo Nordisk Analyser Ladda ner | Visa Stäng
2022-12-21 Nanexa Nanexa tecknar ett exklusivitets- och utvärderingsavtal värt 46,1 MSEK och genomför en riktad emission till Novo Nordisk om 17,2 MSEK Analyser Ladda ner | Visa Stäng
2022-12-06 Nanexa Nanexa has started the Phase 1 study of NEX-20 according to plan Analyser Ladda ner | Visa Stäng
Analyser | 6 Dec 2022 | Nanexa

Nanexa has started the Phase 1 study of NEX-20 according to plan

Nanexa AB (publ) today announced that the first dose of NEX-20 has been administrated in the Phase 1 study NEX-20-01.

NEX-20-01 is a phase 1 study dosing a single injection of NEX-20 to healthy volunteers to follow the pharmacokinetic profile, safety, and tolerability. The study is designed to study different dose levels in sequential dose groups, based on data evaluated during the course of the study.

“Having completed the preclinical program for NEX-20, we will in this study now be able to confirm the depot length of our first PharmaShell® formulation of lenalidomide in humans. These data from healthy volunteers enable our continued planning for dosing of NEX-20 in patients with the life-threatening blood cancer disease multiple myeloma. This is another big step forward for Nanexa on our way to reducing the treatment burden for patients and healthcare providers with the help of PharmaShell®,” says David Westberg, CEO of Nanexa.

NEX-20 is a long-acting formulation of lenalidomide based on Nanexa’s drug delivery system PharmaShell®. Lenalidomide is an immunomodulatory compound targeting both cancer cells and their microenvironment (1). Currently patients take lenalidomide daily as an oral capsule for 21-28 days in 28-day cycles.

Studies show that many patients with multiple myeloma have poor adherence to oral lenalidomide treatment (2). One monthly injection of NEX-20 administered in the clinic would replace daily oral dosing of lenalidomide and would make sure that patients receives the correct dose during treatment. This type of customized depot preparation is promising for patients as you could expect a better clinical effect as a result of improved treatment compliance,” says David Westberg.

References:

  1. A review of the history, properties, and use of the immunomodulatory compound lenalidomide Zeldis et al. Ann N Y Acad Sci. 2011 Mar;1222:76-82
  2. Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma. Hira Mian, Mark Fiala, Tanya M Wildes Clin Lymphoma Myeloma Leuk. 2020;20(2):98-104.e1. doi: 10.1016/j.clml.2019.09.618. Epub 2019 Oct 9. PMID: 31843543
2022-12-06 Nanexa Nanexa har startat Fas 1-studien med NEX-20 enligt plan Analyser Ladda ner | Visa Stäng
2022-11-16 Nanexa Nanexa AB och VitriVax, Inc. har nått en lösning på patentintrångsprocessen Analyser Ladda ner | Visa Stäng
2022-11-16 Nanexa Nanexa AB and VitriVax, Inc. have resolved the patent infringement lawsuit Analyser Ladda ner | Visa Stäng
2022-11-14 Nanexa Nanexa receives approval to start clinical trial with NEX-20 Analyser Ladda ner | Visa Stäng
2022-11-14 Nanexa Nanexa erhåller godkännande att starta klinisk studie med NEX-20 Analyser Ladda ner | Visa Stäng
2022-11-10 Nanexa Nomination Committee for Nanexa AB (publ) Annual General Meeting 2023 Analyser Ladda ner | Visa Stäng
2022-11-10 Nanexa Valberedning inför Nanexa AB (publ) årsstämma 2023 Analyser Ladda ner | Visa Stäng
2022-10-26 Emergers Emergers: Equity Research | NANEXA: Charging to enter triple clinical trials in the coming year Analyser Ladda ner | Visa Stäng
2022-10-25 Nanexa Nanexa publicerar delårsrapport för januari-september 2022 Analyser Ladda ner | Visa Stäng
2022-10-25 Nanexa Nanexa publishes interim report for January – September 2022 Analyser Ladda ner | Visa Stäng
2022-10-24 Nanexa Inbjudan till presentation av Nanexas Q3-rapport 2022 Analyser Ladda ner | Visa Stäng
2022-10-21 Nanexa Nanexa signs evaluation agreement with a Speciality Pharma company Analyser Ladda ner | Visa Stäng
2022-10-21 Nanexa Nanexa tecknar utvärderingsavtal med läkemedelsbolag specialiserat inom ögonområdet Analyser Ladda ner | Visa Stäng
2022-09-27 Nanexa Nanexa AB and Vitrivax, Inc reach agreement in principle Analyser Ladda ner | Visa Stäng
2022-09-27 Nanexa Nanexa AB och Vitrivax, Inc har nått en överenskommelse i alla väsentliga delar Analyser Ladda ner | Visa Stäng
2022-09-19 Emergers Emergers: NANEXA Equity Research Case Video Summary Analyser Ladda ner | Visa Stäng
2022-09-16 Emergers Emergers: Equity Research | NANEXA: New project NEX-22 to add significant daily benefits for 50m patient market Analyser Ladda ner | Visa Stäng
2022-09-15 Nanexa Nanexa startar produktprojektet NEX-22 som adresserar en enorm marknad Analyser Ladda ner | Visa Stäng
2022-09-15 Nanexa Nanexa launches NEX-22 product project to address a huge market Analyser Ladda ner | Visa Stäng
2022-08-30 Nanexa Nanexa signs evaluation agreement with a Global Pharmaceutical Company Analyser Ladda ner | Visa Stäng
2022-08-30 Nanexa Nanexa tecknar utvärderingsavtal med ett stort globalt läkemedelsbolag Analyser Ladda ner | Visa Stäng
2022-08-29 Redeye Redeye: Nanexa - Our Q2 Comment Analyser Ladda ner | Visa Stäng
2022-08-26 Nanexa Nanexa publicerar delårsrapport för januari-juni 2022 Analyser Ladda ner | Visa Stäng
2022-08-26 Nanexa Nanexa publishes interim report for January – June 2022 Analyser Ladda ner | Visa Stäng
2022-08-25 Nanexa Nanexa erhåller utökat GMP certifikat för den nya pilotanläggningen Analyser Ladda ner | Visa Stäng
2022-08-25 Nanexa Nanexa receives extended GMP-certificate for the new pilot plant Analyser Ladda ner | Visa Stäng
2022-07-21 Nanexa Nanexa fördjupar samarbetsavtalet med Applied Materials Analyser Ladda ner | Visa Stäng
2022-07-21 Nanexa Nanexa extends collaboration agreement with Applied Materials Analyser Ladda ner | Visa Stäng
2022-06-13 Emergers Emergers: Equity Research | NANEXA: New facility important step in scaling up activity with eventful year ahead Analyser Ladda ner | Visa Stäng
2022-06-10 Nanexa Lyckad invigning av Nanexas nya pilotanläggning i Uppsala Analyser Ladda ner | Visa Stäng
2022-06-09 Nanexa Bulletin from Nanexa’s Annual General Meeting 2022 Analyser Ladda ner | Visa Stäng
2022-06-09 Nanexa Kommuniké från årsstämma i Nanexa Analyser Ladda ner | Visa Stäng
2022-05-24 Nanexa Nanexa receives grant from VINNOVA for study with monoclonal antibodies Analyser Ladda ner | Visa Stäng
2022-05-24 Nanexa Nanexa beviljas bidrag från VINNOVA för studie med monoklonala antikroppar Analyser Ladda ner | Visa Stäng
2022-05-09 Nanexa Kallelse till årsstämma i Nanexa AB Analyser Ladda ner | Visa Stäng
2022-04-28 Nanexa The European Patent Office has granted Nanexa’s PharmaShell® patent Analyser Ladda ner | Visa Stäng
2022-04-28 Nanexa Europeiska patentverket har godkänt Nanexas PharmaShell®-patent Analyser Ladda ner | Visa Stäng
2022-04-21 Emergers Emergers: Start av Nanexas produktionsanläggning och klinisk studie av NEX-20 fokus 2022 Analyser Ladda ner | Visa Stäng
2022-04-20 Nanexa Nanexa publicerar årsredovisning för 2021 Analyser Ladda ner | Visa Stäng
2022-04-20 Nanexa Nanexa publishes interim report for January – March 2022 Analyser Ladda ner | Visa Stäng
2022-04-20 Nanexa Nanexa publicerar delårsrapport för januari-mars 2022 Analyser Ladda ner | Visa Stäng
2022-04-19 Nanexa Inbjudan till presentation av Nanexas Q1-rapport för 2022 Analyser Ladda ner | Visa Stäng

Kommande händelser

16 Feb 2023 | Bokslutskommuniké 2022